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OBJECTIVES: Eplerenone, indicated to improve survival of
stable patients with left ventricular systolic dysfunction and clin-
ical evidence of congestive heart failure (HF) after an acute
myocardial infarction (postAMI-CHF), has demonstrated to
reduce all cause mortality and HF hospitalization number as well
as the length of stay (LOS). The objective is to estimate total
annual ﬁnancial impact for an example of a tertiary Spanish hos-
pital, based on a formulary including Eplerenone vs. without
Eplerenone. METHODS: The model represents the patterns of
treatment experienced by hospitalized postAMI-CHF patients
during a 1-year period under the hospital perspective (2005). We
estimated the annual discharges with postAMI-CHF number
(422) from the total annual discharges number (62,391) and 
epidemiological data obtained from the literature. Estimated
Eplerenone treatment mean duration was 15 days for the initial
postAMI-CHF. Rates of CHF rehospitalization for postAMI-
CHF patients, and the average of postAMI-CHF hospitalization
LOS were obtained from EPHESUS. Only direct costs were
included: adquisition drug and CHF hospitalization. Results are
detailed as hospital net cost (postAMI-CHF hospitalizations 
and inpatient Eplerenone treatment) and incremental budgetary
impact of having Eplerenone in the formulary. A sensitivity
analysis was carried out varying hospitalization costs and hos-
pitals mean LOS. RESULTS: Annual costs incurred due to
postAMI-CHF hospitalizations were €128,373 with Eplerenone
(Drug cost: €12,817) and €176,022 without Eplerenone. The
hospital savings were €47,649, which represents an annual
saving of 27% with regard to the total expense in these patients.
The use of Eplerenone is overcompensated by the number of
rehospitalization and LOS reduction. Sensitivity analysis results
show an annual saving between €23,274 and €102.932. CON-
CLUSIONS: Using a simulation of what would happen in an
example of a Spanish tertiary hospital, the use of Eplerenone is
associated with a cost saving, under the perspective of the hos-
pital, due to less rehospitalizations and length of stay.
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OBJECTIVES: ARBs were introduced into the UK antihyper-
tensive drug market at a premium price and during a time of
evolving evidence and changes to existing hypertension treat-
ment guidelines. The study aimed to determine the UK antihy-
pertensive drug budget impact since the ﬁrst ARB market launch
December 1994 and what proportion of the increase was directly
attributable to ARBs. METHODS: Prescriptions for oral hyper-
tension treatment were identiﬁed from 1995 through approxi-
mately July 2004 from the Health Improvement Network
(THIN) database, an electronic medical record dataset of
patients seen by general practitioners in the UK. Drug prices were
based on the Chemist&Druggist January 2005 pricelist to esti-
mate real growth in expenditures. Expenditure trends were dis-
aggregated by: (1) treatment prevalence, deﬁned as the number
of patients receiving a prescription for an antihypertensive drug;
(2) antihypertensive prescriptions per patient treated; and (3)
average drug expenditures per antihypertensive prescription.
RESULTS: Expenditures for drugs approved for hypertension
treatment were estimated at 465,862,416 GBP in 1995 and
1,458,268,104 GBP in 2004 (2005 GBP values), reﬂecting a
213% real rate of increase. Use of ARBs accounted for only 5.8
to 9.3 aggregate percentage points of the average drug expendi-
tures. ARB prescription frequency increased from 0.04% in 1995
to 6.57% in 2004. Treatment prevalence rose from 11.30% in
1995 to 16.90% in 2004, while the average annual number of
antihypertensive drug prescriptions per patient increased from
9.32% to 13.46%. The average antihypertensive drug expendi-
tures per antihypertensive drug prescription increased over time
reﬂecting a product shift towards more expensive therapies.
CONLUSIONS: ARBs accounted for less than 10% of the 213%
increase in expenditures on antihypertensive drugs following the
introduction of ARBs in the UK. A substantial portion of the
indirect impact reﬂected increases in treatment prevalence and
increases in the number of prescriptions per patient, including
the use of combination therapies.
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OBJECTIVES: Evaluation of peripheral vascular disease in the
primary care setting is routinely performed by contrast-enhanced
magnetic resonance angiography (CE-MRA) and digital sub-
traction angiography (DSA). However, limited data are available
on the relative costs and clinical outcomes following these diag-
nostic procedures. METHODS: We identiﬁed individuals who
underwent an outpatient CE-MRA (3444) or DSA (16,899) pro-
cedure of the lower extremities from 1998 to 2004 in the U.S.
Veterans Affairs system. Using VA costing algorithms, Cost and
log-cost of interventions (e.g., revascularization, stent, angio-
plasty), amputations or mortality rates within 30 days and one
year of DSA or CE-MRA were compared for both groups
adjusted for baseline characteristics using multivariate regres-
sion. Imaging modality selection bias was evaluated with propen-
sity score, instrumental variables and Heckman methods using
retransformation and Generalized Linear Models. RESULTS:
Initial CE-MRA imaging was signiﬁcantly more likely among
patients with prior renal disease or bypass surgery (OR > 2; p <
0.001) and less likely among patients with prior amputation,
PVD, claudication or other cardiovascular disease markers (OR
< 0.7; p < 0.001). Even after adjusting for endogenous choice 
of initial imaging modality, 30 day treatment costs were
US$3500–$4300 lower (p < 0.001) for imaging patients with
initial CE-MRA. Eighty-two percent (65%) of DSA imaging
patients had no additional procedures or events within 30 (90)
days, and less than 3.2% (3.6%) of patients had any repeat
image within 30 (90) days of their initial image. CONCLU-
SIONS: Relative to DSA, CE-MRA imaging was associated with
substantial treatment episode savings, beyond the US$950 lower
imaging cost per procedure. These savings estimates were robust
to alternate model speciﬁcations and statistical corrections for
endogenous imaging choice. Substituting CE-MRA for DSA
among those not planning or requiring any follow-up procedures
within 30 days could have reduced outpatient imaging costs by
up to 55%, and reduced VA system costs by US$13.2 million.
